Patents by Inventor Paul Flynn

Paul Flynn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SOLID DOSE PHARMACEUTICAL COMPOSITION
    Publication number: 20230390288
    Abstract: The present disclosure provides pharmaceutical compositions comprising a compound having activity as an ACVR1 (ALK2) or ALK5 inhibitor.
    Type: Application
    Filed: August 10, 2023
    Publication date: December 7, 2023
    Applicant: Sumitomo Pharma Oncology, Inc.
    Inventors: Steven L. WARNER, Jason Marc FOULKS, Paul FLYNN
  • CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of Cancer
    Publication number: 20230250116
    Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.
    Type: Application
    Filed: November 10, 2022
    Publication date: August 10, 2023
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Yuji Fujiwara, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
  • FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS
    Publication number: 20230233557
    Abstract: Provided is a composition comprising a polyglycolized glyceride and a compound having the following structure (I): or a pharmaceutically acceptable salt thereof. Also provided are crystalline forms of the compound of structure (I), or a pharmaceutically acceptable salt thereof. Methods of making the same, and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated diseases, disorders or conditions are also disclosed.
    Type: Application
    Filed: September 6, 2022
    Publication date: July 27, 2023
    Applicant: Sumitomo Pharma Oncology, Inc.
    Inventors: Steven L. WARNER, Adam Siddiqui-Jain, Paul Flynn
  • SOLID DOSE PHARMACEUTICAL COMPOSITION
    Publication number: 20230181586
    Abstract: The present disclosure provides pharmaceutical compositions comprising a compound having activity as an ACVR1 (ALK2) or ALK5 inhibitor.
    Type: Application
    Filed: February 14, 2023
    Publication date: June 15, 2023
    Applicant: Sumitomo Pharma Oncology, Inc.
    Inventors: Steven L. WARNER, Jason Marc Foulks, Paul Flynn
  • AXL KINASE INHIBITORS AND USE OF THE SAME
    Publication number: 20230165857
    Abstract: Tartrate salts of the compound of structure (I), , crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.
    Type: Application
    Filed: June 9, 2022
    Publication date: June 1, 2023
    Inventors: Adam Siddiqui-Jain, Steven L. Warner, Paul Flynn, David J. Bearss, Jason Marc Foulks, Nozomi Tomimatsu, Ken Fujimura, Hiroki Umehara, Akihito Nonoyama, Akihito Kiguchiya
  • SOLID DOSE PHARMACEUTICAL COMPOSITION
    Publication number: 20230000864
    Abstract: The present disclosure provides pharmaceutical compositions comprising a compound having activity as an ACVR1 (ALK2) or ALK5 inhibitor.
    Type: Application
    Filed: November 20, 2020
    Publication date: January 5, 2023
    Applicant: SUMITOMO PHARMA ONCOLOGY, INC.
    Inventors: Steven L. WARNER, Jason Marc FOULKS, Paul FLYNN
  • CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
    Patent number: 11530231
    Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.
    Type: Grant
    Filed: April 8, 2021
    Date of Patent: December 20, 2022
    Assignee: Sumitomo Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
  • AXL INHIBITOR FORMULATIONS
    Publication number: 20220380348
    Abstract: Formulations of Compound 1 or a pharmaceutically acceptable salt thereof are described. Also disclosed are capsules having a dry blended powder comprising Compound 1 or a pharmaceutically acceptable salt thereof. The Compound 1 or a pharmaceutically acceptable salt thereof may be a tartrate salt of Compound 1, such as a mono-, sub-, or di-tartrate salt, and including crystalline forms thereof. The formulations may include excipients such as diluents (e.g., microcrystalline cellulose, lactose); disintegrants (e.g., croscarmellose sodium); and lubricants (e.g., magnesium stearate).
    Type: Application
    Filed: October 2, 2020
    Publication date: December 1, 2022
    Inventors: Adam Siddiqui-Jain, Steven L. Warner, Ph.D., Paul Flynn, Akihito NONOYAMA, Akihito Kiguchiya
  • Formulations comprising heterocyclic protein kinase inhibitors
    Patent number: 11471456
    Abstract: Provided is a composition comprising a polyglycolized glyceride and a compound having the following structure (I): or a pharmaceutically acceptable salt thereof. Also provided are crystalline forms of the compound of structure (I), or a pharmaceutically acceptable salt thereof. Methods of making the same, and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated diseases, disorders or conditions are also disclosed.
    Type: Grant
    Filed: February 12, 2020
    Date of Patent: October 18, 2022
    Assignee: Sumitomo Pharma Oncology, Inc.
    Inventors: Steven L. Warner, Adam Siddiqui-Jain, Paul Flynn
  • AXL kinase inhibitors and use of the same
    Patent number: 11400091
    Abstract: Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.
    Type: Grant
    Filed: November 9, 2020
    Date of Patent: August 2, 2022
    Assignee: Sumitomo Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Steven L. Warner, Paul Flynn, David J. Bearss, Jason Marc Foulks, Nozomi Tomimatsu, Ken Fujimura, Hiroki Umehara, Akihito Nonoyama, Akihito Kiguchiya
  • CDK9 Inhibitors and Polymorphs Thereof For Use As Agents For Treatment of Cancer
    Publication number: 20210332071
    Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.
    Type: Application
    Filed: April 8, 2021
    Publication date: October 28, 2021
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Yuji Fujiwara, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
  • AXL KINASE INHIBITORS AND USE OF THE SAME
    Publication number: 20210205304
    Abstract: Tartrate salts of the compound of structure (I), (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.
    Type: Application
    Filed: November 9, 2020
    Publication date: July 8, 2021
    Applicant: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Steven L. Warner, Paul Flynn, David J. Bearss, Jason Marc Foulks, Nozomi Tomimatsu, Ken Fujimura, Hiroki Umehara, Akihito Nonoyama, Akihito Kiguchiya
  • Methods for treating diseases associated with abnormal ACVR1 expression and ACVR1 inhibitors for use in the same
    Patent number: 11040038
    Abstract: Methods for treating a disease in a subject in need thereof by administering an ACVR1 inhibitor having the following formula (I) are disclosed: including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, and R4 are as defined herein. Subjects that may benefit from treatment may have mutations in their ACVR1 gene. Various diseases may be treated using the described methods, including cancers (e.g., diffuse intrinsic pontine glioma (DIPG)) and genetic disorders (e.g., fibrodysplasia ossificans progressiva (FOP)).
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: June 22, 2021
    Assignee: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
    Inventors: Steven L. Warner, David J. Bearss, Adam Siddiqui-Jain, Clifford J. Whatcott, Jason Marc Foulks, Stephen Patrick Anthony, Paul Flynn, Yuji Fujiwara, Yuka Arikawa
  • CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer
    Patent number: 11034710
    Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.
    Type: Grant
    Filed: December 4, 2019
    Date of Patent: June 15, 2021
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Yuji Fujiwara, Shuji Masumoto, Hiroaki Tanaka, Hirotaka Kurebayashi, Takahiko Hashizuka, Yuka Arikawa
  • AXL kinase inhibitors and use of the same
    Patent number: 11013741
    Abstract: Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: May 25, 2021
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Akihito Nonoyama, Akihito Kiguchiya
  • AXL kinase inhibitors and use of the same
    Patent number: 10888562
    Abstract: Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 12, 2021
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Akihito Nonoyama, Akihito Kiguchiya
  • FORMULATIONS COMPRISING HETEROCYCLIC PROTEIN KINASE INHIBITORS
    Publication number: 20200338076
    Abstract: Provided is a composition comprising a polyglycolized glyceride and a compound having the following structure (I): or a pharmaceutically acceptable salt thereof. Also provided are crystalline forms of the compound of structure (I), or a pharmaceutically acceptable salt thereof. Methods of making the same, and methods for using the same in the treatment of cancer, autoimmune, inflammatory and other Pim kinase-associated diseases, disorders or conditions are also disclosed.
    Type: Application
    Filed: February 12, 2020
    Publication date: October 29, 2020
    Inventors: Steven L. WARNER, Adam SIDDIQUI-JAIN, Paul FLYNN
  • CDK9 INHIBITORS AND POLYMORPHS THEREOF FOR USE AS AGENTS FOR TREATMENT OF CANCER
    Publication number: 20200255462
    Abstract: A crystalline form and/or polymorph of a compound having the following structure (I), including tautomeric and zwitterionic forms thereof, are provided: Methods associated with preparation and use of the polymorphs, and pharmaceutical compositions comprising the same are also provided. Also provided are methods for preparing a compound having formula (I), or a salt, tautomer or zwitterionic form thereof.
    Type: Application
    Filed: December 4, 2019
    Publication date: August 13, 2020
    Inventors: Adam SIDDIQUI-JAIN, Paul FLYNN, Yuji FUJIWARA, Shuji MASUMOTO, Hiroaki TANAKA, Hirotaka KUREBAYASHI, Takahiko HASHIZUKA, Yuka ARIKAWA
  • METHODS FOR TREATING DISEASES ASSOCIATED WITH ABNORMAL ACVR1 EXPRESSION AND ACVR1 INHIBITORS FOR USE IN THE SAME
    Publication number: 20200085823
    Abstract: Methods for treating a disease in a subject in need thereof by administering an ACVR1 inhibitor having the following formula (I) are disclosed: including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, and R4 are as defined herein. Subjects that may benefit from treatment may have mutations in their ACVR1 gene. Various diseases may be treated using the described methods, including cancers (e.g., diffuse intrinsic pontine glioma (DIPG)) and genetic disorders (e.g., fibrodysplasia ossificans progressiva (FOP)).
    Type: Application
    Filed: July 26, 2019
    Publication date: March 19, 2020
    Inventors: Steven L. Warner, David J. Bearss, Adam Siddiqui-Jain, Clifford J. Whatcott, Jason Marc Foulks, Stephen Patrick Anthony, Paul Flynn, Yuji Fujiwara, Yuka Arikawa
  • MAGNESIUM PHOSPHATE BIOMATERIALS
    Publication number: 20190192725
    Abstract: There is provided a solid cement reactant comprising a dehydrated magnesium phosphate, and/or an amorphous or partially amorphous magnesium phosphate, and/or Farringtonite.
    Type: Application
    Filed: April 25, 2018
    Publication date: June 27, 2019
    Inventors: Jake Edward Barralet, Faleh Ahmad Tamimi Marino, Andrew Paul Flynn